Asia Pacific Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiologica

Asia Pacific Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiological Procedures {Lymphovenous Anastomosis (LVA) and Vascularized Lymph Node Transfer (VLNT)}, Debulking Procedures {Surgical Debulking, Liposuction, and Others}, and Others), and End User (Hospitals, Clinics, Clinical Research Organizations, and Others) 

The lymphedema treatment market in APAC is expected to grow from US$ 975.11 million in 2021 to US$ 1,546.52 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2021 to 2028. The utility of robotics for lymphatic surgery allows much greater flexibility and precision compared to previously used laparoscopy. Additionally, the use of robotics proves optimal for both surgeon and patient outcomes and reveals positive results. For instance, patients who underwent the single-robotic surgery for lymphedema in May 2020 provided positive anecdotal feedback, including significant clinical improvement such as the ability to wear clothes with the surgeon's significant accomplishments. Further, robots enabled with artificial intelligence (AI) are increasingly assisting in lymphedema surgeries' microsurgical procedures to reduce surgeon variations that could affect patient recovery. For example, for lymphedema surgery, in May 2020, an urogynecology surgeon performed a first-of-its-kind single-port robotic mental harvest by utilizing a free lymph node transfer, intended for minimally invasive surgical treatment of lymphedema. The main objective of this new surgical treatment method was to minimize donor site morbidity with debilitating lymphedema symptoms. Thus the growing use of robotics is fueling market growth.

The compression devices and bandaging segment led the APAC lymphedema treatment market, based on treatment type, in 2020. The compression treatment reduces swelling caused by a buildup of lymph fluid (lymphedema). The pressure exerted by such compression devices helps the trapped lymph fluid to flow through the lymph vessels. Additionally, such devices act as an extra force for the muscles to work satisfactorily in favor of lymphedema patients. Further, bandaging for lymphedema is called multi-layered lymphedema bandaging (MLLB). The main aim is to help lymph fluid drain and stop building up and assist parts of the body to get back to their normal shape. The factors mentioned above positively impact the overall segment growth, ultimately contributing to the growth of the market.

The 2019 novel coronavirus (2019-nCoV), officially named COVID-19 by the WHO, had spread to more than 180 countries, including China, prompting the WHO to declare the disease a global pandemic. The supply chain disturbances and the tremendous demand for efficient treatments for the therapy of COVID-19 had put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures had been taken to control the spread of this pandemic. Countries such as India, China, Japan, South Korea were adversely affected by the COVID-19 pandemic. The socioeconomics was severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. The outbreak severely affected the medical tourism industry in Asia pacific and imposed supply chain disruptions. Further, low-income countries face additional challenges due to the shortage of healthcare infrastructure, restrictions imposed by hospitals to the suppliers, decreasing demand for cardiovascular surgical instruments, and others. There are various research studies on the reduction of surgeries in the Asia Pacific countries. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. These restrictive measures impacted the supply chain and the availability of medical devices in these countries. Furthermore, business strategies such as acquisitions, mergers, and partnerships are adversely affected by the imposition of complete lockdown. However, increasing vaccination across the region and availability of government reimbursement policies for various diseases is expected to normalize the situation in the Asia Pacific region and will gradually increase the demand for lymphedema treatment.

The overall APAC lymphedema treatment market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast of the APAC lymphedema treatment market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data and to gain more analytical insights into the topic. The participants typically involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the APAC lymphedema treatment market. 3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are a few key players operating in the market in this region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the APAC lymphedema treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC lymphedema treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the lymphedema treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution